Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.57 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CCND3 | P30281 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652721 | 0.94 | KMT2A (0.55) | FGFR1FGFR2FGFR3KDRCYP2C9 | |
| SCHEMBL5651417 | 0.91 | CYP2C9 (0.61) | FGFR1FGFR2FGFR3KDRCYP2C9 | |
| SCHEMBL5654261 | 0.91 | FGFR1 (0.57) | FGFR1FGFR2FGFR3KDRCYP2C9 | |
| SCHEMBL5651930 | 0.91 | FGFR1 (0.58) | FGFR1FGFR2FGFR3KDRCYP2C9 | |
| SCHEMBL5650235 | 0.88 | CYP2C9 (0.56) | FGFR1FGFR2FGFR3KDRCYP2C9 | |
| SCHEMBL5653653 | 0.88 | FGFR1 (0.58) | FGFR1FGFR2FGFR3KDRCYP2C9 | |
| SCHEMBL5648124 | 0.86 | TSHR (0.52) | FGFR1FGFR2FGFR3KDRCYP2C9 | |
| SCHEMBL5653274 | 0.85 | TSHR (0.52) | CYP2C9CYP2D6MEN1KMT2ATSHR | |
| SCHEMBL5651436 | 0.85 | CYP2C9 (0.61) | FGFR1FGFR2FGFR3KDRCYP2C9 | |
| SCHEMBL5654271 | 0.85 | KMT2A (0.56) | FGFR1FGFR2FGFR3KDRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | FGFR1 1208/4885FGFR2 1535/4885FGFR3 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.